All > New Mexico > Colorado

ZN-c3 for Platinum-resistant Ovarian Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Platinum-resistant Ovarian Cancer+3 MoreZN-c3 - Drug
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

This trial is testing a new combination drug treatment for women with ovarian cancer that has stopped responding to other treatments.

Eligible Conditions
  • Platinum-resistant Ovarian Cancer
  • Ovarian Cancer
  • Primary Peritoneal Carcinoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
ZN-c3
1
BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
1
ZN-c3

Study Objectives

3 Primary · 10 Secondary · Reporting Duration: 30 months

12 months
Phase 2: To investigate the antitumor activity of ZN-c3 in combination with niraparib - Progression Free Survival at 4 months
18 months
Phase 2: To investigate the antitumor activity of ZN-c3 in combination with niraparib - Objective Response Rate
30 months
To evaluate changes in Patient Reported Outcomes (PROs) and quality of life
To further investigate the antitumor activity of ZN-c3 in combination with niraparib - Clinical Benefit Rate
To further investigate the antitumor activity of ZN-c3 in combination with niraparib - Duration of response
To further investigate the antitumor activity of ZN-c3 in combination with niraparib - Objective Response Rate
To investigate the OS of subjects receiving ZN-c3 in combination with niraparib
To investigate the PD and downstream effects of ZN-c3 when given in combination with niraparib - Baseline Cyclin E expression
Body Weight Changes
To investigate the PD and downstream effects of ZN-c3 when given in combination with niraparib - Molecular determinants of sensitivity to ZN-c3
To investigate the plasma PK of ZN-c3 and niraparib when given in combination - Area under the plasma concentration-time curve from 0 to 24h
Plasma Exchange
To investigate the plasma PK of ZN-c3 and niraparib when given in combination - Time to maximum plasma concentration
To investigate the plasma PK of ZN-c3 and niraparib when given in combination - Trough concentration
To investigate the safety and tolerability of ZN-c3 in combination with niraparib
6 months
Phase 1: Incidence and severity of Dose Limiting Toxicities (DLTs) in DLT-evaluable subjects during Cycle 1

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
ZN-c3
1
BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
1
ZN-c3

Side Effects for

FE Niraparib Fasted
6%Anaemia
6%Urinary tract infection
6%Diarrhoea
6%Blood creatinine increased
6%Decreased appetite
6%Hypokalaemia
6%Hypomagnesaemia
6%Cough
6%Catheter site pain
6%Atrial fibrillation
6%Dry eye
This histogram enumerates side effects from a completed 2021 Phase 3 trial (NCT01847274) in the FE Niraparib Fasted ARM group. Side effects include: Anaemia with 6%, Urinary tract infection with 6%, Diarrhoea with 6%, Blood creatinine increased with 6%, Decreased appetite with 6%.

Trial Design

1 Treatment Group

ZN-c3 and Niraparib
1 of 1

Experimental Treatment

138 Total Participants · 1 Treatment Group

Primary Treatment: ZN-c3 · No Placebo Group · Phase 1 & 2

ZN-c3 and NiraparibExperimental Group · 2 Interventions: Niraparib, ZN-c3 · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Niraparib
2018
Completed Phase 4
~1000

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 30 months

Who is running the clinical trial?

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncLead Sponsor
5 Previous Clinical Trials
534 Total Patients Enrolled
K-Group BetaLead Sponsor
5 Previous Clinical Trials
534 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Female Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have demonstrated relapse within 6 months of platinum therapy.
You have evaluable or measurable disease according to RECIST v1.
You have measurable disease according to RECIST V1.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top